KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBITDA: 2010-2024

Historic EBITDA for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -$4.8 million.

  • TherapeuticsMD's EBITDA rose 23.99% to -$862,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 70.95%. This contributed to the annual value of -$4.8 million for FY2024, which is 53.69% up from last year.
  • TherapeuticsMD's EBITDA amounted to -$4.8 million in FY2024, which was up 53.69% from -$10.3 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's EBITDA registered a high of $112.0 million during FY2022, and its lowest value of -$183.5 million during FY2020.
  • In the last 3 years, TherapeuticsMD's EBITDA had a median value of -$4.8 million in 2024 and averaged $32.3 million.
  • In the last 5 years, TherapeuticsMD's EBITDA surged by 164.96% in 2022 and then slumped by 109.18% in 2023.
  • Over the past 5 years, TherapeuticsMD's EBITDA (Yearly) stood at -$183.5 million in 2020, then rose by 6.05% to -$172.4 million in 2021, then spiked by 164.96% to $112.0 million in 2022, then plummeted by 109.18% to -$10.3 million in 2023, then skyrocketed by 53.69% to -$4.8 million in 2024.